Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALAPRO-3: Talazoparib + Enzalutamide in DDR-Mutated mCSPC
NCT04821622Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- May 2021
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 27
01
Overview
A Phase 3 trial of talazoparib in prostate cancer (PCa), sponsored by Pfizer. Started May 2021; status: active, not recruiting.
02
Drugs
talazoparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04821622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04821622.